Drop in Rx drug spending contributes to decline in US healthcare growth: report

Share this article:
A sharply lower growth in the rise of prescription drug spending contributed to the slowdown in growth of US healthcare spending for the third consecutive year, the results of a federal study reported today in the Wall Street Journal shows. The government study, to be released today, is considered to be the most comprehensive tally of the nation’s annual health spending. According to the results, the US spent $1.9 trillion, or $6,697 per person, on healthcare in 2005, the latest year for which data are available. That was a rise of 6.9%, down from 7.2% in 2004 and the lowest growth rate since 1999. The slowdown in prescription drug spending has been notable – spending increased only 5.8% in 2005, down from 8.6% in 2004 and a peak of 18.2% in 1999, the report said. The drop in drug spending was partly caused by as sharp deceleration in drug expenditures by Medicaid. Drug spending by Medicaid rose 2.8% in 2005, compared with average annual increases of 15.4% for the program from 1994 to 2004. To restrain costs, states have worked together to get higher rebates on certain drugs and steered recipients to use those drugs. The withdrawal of Merck’s Vioxx also dampened spending, the report said. The study does not include data on the effect of the Medicare drug benefit, which was implemented in January 2006.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...